Karoui Sami, Hamrouni Asma, Bibani Norsaf, Serghini Meriem, Boubaker Jalel, Filali Azza
Service de Gastroenterologie, Hopital la Rabta, Tunis, Tunisie.
Tunis Med. 2011 Jul;89(7):610-5.
Immunosupressors, particularly azathioprine, represents the therapeutic alternative in patients with corticodependant or corticoresistant Crohn's disease. The prescription of azathioprine in Tunisia is common, but there is not Tunisian studies evaluating the long term results of this drug in Crohn's disease patients.
To evaluate the long term results of azathioprine treatment with determination of rates of relapses, surgery and need to corticosteroids in patients with corticodependant or corticoresistant Crohn's disease, and to look for predictive factors to theses events.
A retrospective study on 12 years including all patients treated by azathioprine for corticodependant or corticoresistant Crohn's disease. We excluded the cases of follow up less than 6 months.
We studied 56 patients (46 corticodependant and 10 corticoresistant). Induction of remission was obtained in 89% of the cases. Concerning the long term results, the relapse rate was 60% of patients treated with azathioprine, with actuarial rates of 38% at one year, 65% at 5 years and 75% at 10 years. Need for corticosteroid treatment was estimated at 42% and need for surgical treatment was estimated at 24%. The only predictive factor for relapse was duration of treatment by azathioprine more than 36 months, with sensitivity of 93% and specificity of 50%.
Although an excellent result of azathioprine in induction remission, long term results showed deterioration of results of treatment. Physicians must be followed up Crohn's disease patients in order to rapidly detect and treat the clinical relapses of the disease.
免疫抑制剂,尤其是硫唑嘌呤,是皮质激素依赖型或皮质激素抵抗型克罗恩病患者的治疗选择。在突尼斯,硫唑嘌呤的处方很常见,但尚无突尼斯的研究评估该药物在克罗恩病患者中的长期疗效。
评估硫唑嘌呤治疗皮质激素依赖型或皮质激素抵抗型克罗恩病患者的长期疗效,确定复发率、手术率和使用皮质类固醇的必要性,并寻找这些事件的预测因素。
一项为期12年的回顾性研究,纳入所有接受硫唑嘌呤治疗的皮质激素依赖型或皮质激素抵抗型克罗恩病患者。排除随访时间少于6个月的病例。
我们研究了56例患者(46例皮质激素依赖型和10例皮质激素抵抗型)。89%的病例实现了缓解诱导。关于长期疗效,接受硫唑嘌呤治疗的患者复发率为60%,1年的精算复发率为38%,5年为65%,10年为75%。估计42%的患者需要皮质类固醇治疗,24%的患者需要手术治疗。复发的唯一预测因素是硫唑嘌呤治疗时间超过36个月,敏感性为93%,特异性为50%。
尽管硫唑嘌呤在诱导缓解方面效果良好,但长期疗效显示治疗效果恶化。医生必须对克罗恩病患者进行随访,以便快速发现并治疗该疾病的临床复发。